Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
Add more filters










Publication year range
1.
PLoS One ; 18(1): e0280331, 2023.
Article in English | MEDLINE | ID: mdl-36630412

ABSTRACT

Omidenepag isopropyl (OMDI) is an intraocular pressure (IOP)-lowering drug used to treat glaucoma. The active form of OMDI, omidenepag (OMD), lowers elevated IOP, the main risk factor for glaucoma, by increasing the aqueous humor outflow; however, a detailed understanding of this mechanism is lacking. To clarify the IOP-lowering mechanism of OMDI, the effects of OMD on the mRNA expression of the extracellular matrix, matrix metalloproteinases (MMPs), and tissue inhibitors of metalloproteinases (TIMPs) were evaluated in human trabecular meshwork cells. Under 2D culture conditions, the mRNA expression of FN1, COL1A1, COL1A2, COL12A1, and COL13A1 decreased in a concentration-dependent manner after 6 or 24 h treatment with 10 nM, 100 nM, and 1 µM OMD, while that of COL18A1 decreased after 6 h treatment with 1 µM OMD. Significant changes in expression were observed for many MMP and TIMP genes. Under 3D culture conditions, the extracellular matrix-related genes COL12A1 and COL13A1 were downregulated by OMD treatment at all three concentrations. Under both 2D and 3D culture conditions, COL12A1 and COL13A1 were downregulated following OMD treatment. Reduction in the extracellular matrix contributes to the decrease in outflow resistance, suggesting that the downregulation of the two related genes may be one of the factors influencing the IOP-lowering effect of OMDI. Our findings provide insights for the use of OMDI in clinical practice.


Subject(s)
Glaucoma , Trabecular Meshwork , Humans , Trabecular Meshwork/metabolism , Down-Regulation , Glaucoma/drug therapy , Glaucoma/genetics , Glaucoma/metabolism , Intraocular Pressure , Aqueous Humor/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Collagen Type XII/metabolism
2.
Transl Vis Sci Technol ; 11(4): 9, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35404438

ABSTRACT

Purpose: To evaluate tissue reactivity to, and the stability of, glaucoma drainage device materials placed under rabbit conjunctiva in vivo. Methods: Disks (diameter, 3 mm; thickness, ∼0.3 mm) fabricated from poly(styrene-block-isobutylene-block-styrene) (SIBS), silicone, stainless-steel, or glutaraldehyde cross-linked collagen (GACLC) were inserted under rabbit conjunctiva. Conjunctival and scleral sections obtained at 4, 8, and 12 weeks after surgery were immunostained for α-smooth muscle actin (SMA). The ratio of the maximum thickness of the α-SMA-positive conjunctiva to the scleral thickness (α-SMA/S ratio) was calculated. The in vivo stability of the drainage devices at 12 weeks after insertion was evaluated. Results: The mean α-SMA/S ratios of the SIBS and silicone groups were lower than that of the stainless-steel group at 4 weeks after surgery (P < 0.05), and that of the SIBS group was lower than that of the GACLC group (P < 0.05). The ratios at 8 weeks after surgery were lower in the SIBS and silicone groups than in the GACLC group (P < 0.01). The ratios at 12 weeks after surgery were lower in the SIBS and silicone groups than in the GACLC group (P < 0.05). The surface areas of GACLC disks explanted from conjunctivae were significantly lower than that of intact disks (P < 0.01). Conclusions: SIBS and silicon were highly biostable and exhibited less tissue reactivity than GACLC in vivo. Translational Relevance: Comparisons of materials using animal models can predict the clinical stability and safety of such materials in humans.


Subject(s)
Glaucoma Drainage Implants , Animals , Conjunctiva/surgery , Rabbits , Silicones , Steel , Styrene
3.
Transl Vis Sci Technol ; 10(9): 9, 2021 08 02.
Article in English | MEDLINE | ID: mdl-34357381

ABSTRACT

Purpose: To compare the surgical results of PRESERFLO MicroShunt (MicroShunt) insertion and trabeculectomy in rabbit eyes. Methods: Trabeculectomy or MicroShunt insertion was performed on the eyes of Japanese white rabbits. Intraocular pressure (IOP) was measured on conscious rabbits using a rebound tonometer for up to 12 weeks after surgery. Filtering bleb appearance was evaluated. Scarring in the filtering bleb was assessed by immunohistochemical analyses. The change in mRNA expression in the conjunctiva was evaluated using RNA sequence analyses. Results: The preoperative IOP of the operative eye did not differ significantly between trabeculectomy (11.6 ± 1.0 mmHg, n = 10) and MicroShunt insertion (12.6 ± 1.3 mmHg, n = 10). In both groups, the IOP of the operative eye was significantly lower than that of the contralateral eye at one day postoperatively, which continued until 12 weeks after surgery. The peak differences in IOP were -8.4 ± 3.0 (trabeculectomy) and -8.1 ± 2.1 mmHg (MicroShunt) at two weeks after surgery; no significant differences were observed in IOP reduction between the groups. Appearance and immunohistochemical analyses of the filtering bleb showed no significant difference between the groups. Moreover, RNA sequence analysis results showed no difference between the groups in mRNA expression fluctuations. Conclusions: Postoperative IOP, bleb appearance, and immunohistochemical analysis results were similar in the trabeculectomy and MicroShunt groups, indicating that MicroShunt insertion is as effective as trabeculectomy in lowering IOP. Translational Relevance: Comparison of surgical procedures using animal models has made it possible to predict clinical efficacy and safety.


Subject(s)
Glaucoma , Trabeculectomy , Animals , Glaucoma/surgery , Intraocular Pressure , Rabbits , Sclera , Tonometry, Ocular
4.
J Ocul Pharmacol Ther ; 37(4): 223-229, 2021 05.
Article in English | MEDLINE | ID: mdl-33600237

ABSTRACT

Purpose: To investigate the intraocular pressure (IOP)-lowering effects of omidenepag isopropyl (OMDI), a potent and highly selective prostanoid EP2 receptor agonist, as a potential first-line ocular hypotensive agent when combined with existing antiglaucoma agents in conscious ocular normotensive monkeys. Methods: Male cynomolgus monkeys were examined under conscious conditions. OMDI ophthalmic solution alone was topically applied to an eye or combined with other ophthalmic solutions at 5-min intervals. The contralateral eye was left untreated. IOP was measured before and at 2, 4, 6, and 8 h after instillation. Results: Topical application of OMDI to the eye resulted in statistically significant IOP reduction, which lasted for at least 6 h. The IOP-lowering effects of OMDI concomitantly administered with any of the tested antiglaucoma agents (timolol, brinzolamide, netarsudil, ripasudil, and brimonidine) were greater than those of OMDI alone. Furthermore, these enhanced IOP responses to their concomitant use were statistically significant compared with those of the tested antiglaucoma agents alone. Any combination of OMDI with the tested agents did not lead to serious abnormalities either systemically or locally in the eye. Conclusions: We demonstrated that OMDI has additive IOP-lowering effects when administered in combination with various antiglaucoma agents, namely, ß-adrenergic antagonist, carbonic anhydrase inhibitor, Rho-associated coiled-coil containing protein kinase inhibitors, and α2-adrenergic agonist. These results suggest that OMDI provides additional clinical benefits because of its unique mechanisms of action when combination therapy is required.


Subject(s)
Glaucoma/drug therapy , Glycine/analogs & derivatives , Intraocular Pressure/drug effects , Pyrazoles/pharmacology , Pyridines/pharmacology , Receptors, Prostaglandin E, EP2 Subtype/agonists , rho-Associated Kinases/antagonists & inhibitors , Administration, Topical , Adrenergic alpha-2 Receptor Agonists/administration & dosage , Adrenergic beta-Antagonists/administration & dosage , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/pharmacology , Carbonic Anhydrase Inhibitors/administration & dosage , Case-Control Studies , Consciousness , Drug Synergism , Drug Therapy, Combination/adverse effects , Drug Therapy, Combination/statistics & numerical data , Glycine/administration & dosage , Glycine/pharmacology , Macaca fascicularis , Male , Ophthalmic Solutions/administration & dosage , Pyrazoles/administration & dosage , Pyridines/administration & dosage , Tonometry, Ocular/methods , rho-Associated Kinases/metabolism
5.
Sci Rep ; 9(1): 19288, 2019 12 17.
Article in English | MEDLINE | ID: mdl-31848363

ABSTRACT

Treatments for refractory glaucoma include trabeculectomy, in which a filtering bleb is created to reduce aqueous pressure. Mitomycin C (MMC) is often used as an adjuvant to reduce post-trabeculectomy bleb scarring and consequent failure. However, scarring sometimes still occurs. Thus, we searched for more effective trabeculectomy adjuvants with high-throughput screening (HTS) of a library of 1,165 off-patent drug compounds. This revealed that amsacrine (AMSA), a DNA topoisomerase II (TOP2) inhibitor, was the top candidate. Compared to MMC, rabbits that underwent trabeculectomy with 10% AMSA had lower IOP at 42, 56, and 70 days (P < 0.01 at all measurement points) and a higher bleb score at 28, 42, 56, and 70 days (P = < 0.01, 0.04, 0.04, and < 0.01, respectively). Compared to saline, rabbits that received 1% AMSA also had lower IOP and better bleb score at all time points, without a sharp drop in IOP just after surgery (all P < 0.01). Both effects were milder than MMC at 7 days (P = 0.02 and <0.01, respectively). Thus, this study showed that HTS may help identify new, promising uses for off-patent drugs. Furthermore, trabeculectomy with AMSA at a suitable concentration may improve the prognosis after trabeculectomy compared to MMC.


Subject(s)
Amsacrine , Glaucoma Drainage Implants , Glaucoma , Trabeculectomy , Animals , Humans , Amsacrine/pharmacology , Callithrix , Cicatrix/prevention & control , Conjunctiva/drug effects , Disease Models, Animal , DNA Topoisomerases, Type II/drug effects , DNA Topoisomerases, Type II/genetics , Filtering Surgery , Glaucoma/drug therapy , Glaucoma/pathology , Glaucoma/surgery , Glaucoma Drainage Implants/adverse effects , Intraocular Pressure/drug effects , Primary Cell Culture , Topoisomerase II Inhibitors/pharmacology , Trabeculectomy/adverse effects
6.
Sci Rep ; 9(1): 7491, 2019 05 16.
Article in English | MEDLINE | ID: mdl-31097790

ABSTRACT

In this study, we made a comparative efficacy and safety assessment of two different fixed combinations of drugs, viz., tafluprost/timolol (TAF/TIM) and latanoprost/carteolol (LAT/CAR), by determining their effects on intraocular pressure (IOP) in ocular normotensive monkeys and examining their toxic effects on ocular surface using human corneal epithelial cells. TAF/TIM was found to be more effective in lowering IOP for a longer duration compared to LAT/CAR. We found that the difference in the intensity of IOP-lowering effect was because of the differences in the strength of timolol compared with that of carteolol as a beta-adrenergic antagonist and strength of tafluprost compared with that of latanoprost as a prostaglandin analogue. In addition, TAF/TIM showed much less cytotoxic effects compared to LAT/CAR on the human corneal epithelial cells. Our findings showed that TAF/TIM is better than LAT/CAR with regard to the IOP-lowering effect in monkeys and toxicity on ocular surface.


Subject(s)
Antihypertensive Agents/adverse effects , Carteolol/adverse effects , Intraocular Pressure/drug effects , Latanoprost/adverse effects , Prostaglandins F/adverse effects , Timolol/adverse effects , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/pharmacology , Carteolol/administration & dosage , Carteolol/pharmacology , Cell Line , Drug Combinations , Epithelium, Corneal/drug effects , Humans , Latanoprost/administration & dosage , Latanoprost/pharmacology , Macaca fascicularis , Male , Prostaglandins F/administration & dosage , Prostaglandins F/pharmacology , Timolol/administration & dosage , Timolol/pharmacology
7.
PLoS One ; 14(3): e0213811, 2019.
Article in English | MEDLINE | ID: mdl-30889194

ABSTRACT

PURPOSE: To investigate the potential of colchicine to improve bleb function after trabeculectomy. METHODS: To find the maximum usable colchicine concentration, an ocular irritation study was performed with the Draize test at concentrations of 0.001%, 0.01% and 0.1%. Additionally, the synergistic effect of topical colchicine instillation and MMC application to surgical site was evaluated in a rabbit model by measuring changes after trabeculectomy in intraocular pressure (IOP) and bleb morphology score at 3, 7, 14, 21, 28, 35, 42, and 49 days. RESULTS: Experiments with a rabbit model of trabeculectomy showed that 0.04% MMC plus 0.01% colchicine was more effective than saline and 0.04% MMC alone in maintaining IOP reduction at days 7-49 (P < 0.01 at all time points) and day 49 (P < 0.05), respectively, while 0.04% MMC alone was more effective than saline only at days 7-35 (P < 0.05 at all time points). 0.04% MMC plus 0.01% colchicine and 0.04% MMC alone were more effective than saline at preserving bleb score at days 7-21 and 35-49 (P < 0.05 at all time points) and at days 7-35 (P < 0.05 at all time points), respectively. CONCLUSION: Colchicine may be a promising adjuvant for strengthening the effect of MMC and improving the survival of the filtering bleb in trabeculectomy.


Subject(s)
Blister/drug therapy , Colchicine/therapeutic use , Eye Diseases/drug therapy , Mitomycin/therapeutic use , Neovascularization, Pathologic/drug therapy , Trabeculectomy/methods , Alkylating Agents/therapeutic use , Animals , Blister/physiopathology , Blister/surgery , Drug Therapy, Combination , Eye Diseases/surgery , Male , Neovascularization, Pathologic/surgery , Rabbits , Tubulin Modulators/therapeutic use
8.
Invest Ophthalmol Vis Sci ; 59(1): 145-153, 2018 01 01.
Article in English | MEDLINE | ID: mdl-29332128

ABSTRACT

Purpose: The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than other prostanoid receptor agonists such as prostaglandin F receptor (FP) agonists. Methods: Binding activities of OMDI and its hydrolyzed form, omidenepag (OMD), to human recombinant prostanoid receptors (DP1-2, EP1-4, FP, and IP) were evaluated. Based on these binding assays, the agonistic activities of OMDI and OMD were further evaluated using cultured cells expressing selected prostanoid receptors. The pharmacokinetics of OMDI after topical administration was assessed in rabbits by measurement of the concentrations of both OMDI and OMD in aqueous humor. The ocular hypotensive effect of OMDI was evaluated in ocular normotensive rabbits, dogs, and both ocular normotensive and hypertensive monkeys. Results: OMD was determined to be a selective EP2 receptor agonist. OMDI weakly bound to EP1; however, the agonistic activity of OMDI to this receptor was not demonstrated in the functional assay. After topical administration of OMDI, OMD was detected in aqueous humor whereas OMDI was not detectable. OMDI significantly lowered IOP in both ocular normotensive and hypertensive animals. The significant ocular hypotensive effects of OMDI were demonstrated by both single and repeated dosing, and its effective duration suggests sufficient efficacy by once-daily dosing. Conclusions: These studies demonstrated that OMDI is hydrolyzed in the eye to OMD, an EP2 receptor agonist, with a significant ocular hypotensive effect in both ocular normotensive and hypertensive animal models.


Subject(s)
Antihypertensive Agents/pharmacokinetics , Aqueous Humor/metabolism , Glaucoma/drug therapy , Intraocular Pressure/drug effects , Receptors, Prostaglandin E, EP2 Subtype/agonists , Administration, Topical , Animals , Antihypertensive Agents/administration & dosage , Disease Models, Animal , Glaucoma/metabolism , Macaca fascicularis , Rabbits
9.
PLoS One ; 11(7): e0158797, 2016.
Article in English | MEDLINE | ID: mdl-27383260

ABSTRACT

PURPOSE: To compare the safety and efficacy of fixed-dose tafluprost/timolol combination (Taf/T-FDC) with those of fixed-dose latanoprost/timolol combination (Lat/T-FDC) by measuring the intraocular pressure (IOP)-lowering effect, ocular pharmacokinetics, and ocular surface toxicity. METHODS: The IOP-lowering effect of Taf/T-FDC and Lat/T-FDC in ocular normotensive monkeys was evaluated at 4 and 8 h after instillation in study A, at 12, 14, 16, and 18 h after instillation in study B, and at 24, 26, 28, and 30 h after instillation in study C. Drug penetration into the eye was evaluated by measuring the concentrations of timolol, tafluprost acid (active metabolic form of tafluprost), and latanoprost acid (active metabolic form of latanoprost) using liquid chromatography coupled with tandem mass spectrometry after single instillation of Taf/T-FDC or Lat/T-FDC to Sprague Dawley rats. Cytotoxicity following 1-30 min exposure of SV40-transformed human corneal epithelial cells to Taf/T-FDC or Lat/T-FDC was analyzed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays. Undiluted and 10-fold diluted solutions of each FDC were evaluated. RESULTS: The IOP-lowering effect of Taf/T-FDC was almost equivalent to that of Lat/T-FDC at 4-8 h after instillation. The peak IOP reduction of Taf/T-FDC and Lat/T-FDC was observed at 8 h after instillation, and there is no difference between the two. The difference between them was observed at 24-30 h after instillation, and Taf/T-FDC demonstrated a significantly greater IOP-lowering effect than Lat/T-FDC at 24-30 h after instillation. The IOP-lowering effect of Taf/T-FDC was sustained up to 30 h after instillation, while that of Lat/T-FDC had almost disappeared at 28 h after instillation. Timolol concentrations in aqueous humor after Taf/T-FDC instillation were higher than those after Lat/T-FDC instillation (Cmax, 3870 ng/mL vs 1330 ng/mL; AUCinf, 3970 ng·h/mL vs 1250 ng·h/mL). The concentrations of tafluprost acid and latanoprost acid in aqueous humor after instillation of Taf/T-FDC and Lat/T-FDC, respectively, were similar to those after instillation of mono-preparations of tafluprost and latanoprost, respectively. The cytotoxic effect of Taf/T-FDC to the human corneal epithelial cells was significantly lower than that of Lat/T-FDC at all evaluated time points in both undiluted and 10-fold diluted FDCs. CONCLUSION: Taf/T-FDC provides increased IOP-lowering effect duration and lower potential ocular surface toxicity than Lat/T-FDC.


Subject(s)
Intraocular Pressure/drug effects , Prostaglandins F, Synthetic/pharmacology , Prostaglandins F/pharmacology , Timolol/pharmacology , Animals , Antihypertensive Agents/pharmacokinetics , Antihypertensive Agents/pharmacology , Area Under Curve , Cell Line , Chromatography, Liquid , Disease Models, Animal , Drug Combinations , Female , Glaucoma/drug therapy , Glaucoma/metabolism , Glaucoma/physiopathology , Humans , Intraocular Pressure/physiology , Latanoprost , Macaca fascicularis , Male , Metabolic Clearance Rate , Ocular Hypertension/drug therapy , Ocular Hypertension/metabolism , Ocular Hypertension/physiopathology , Prostaglandins F/pharmacokinetics , Prostaglandins F, Synthetic/pharmacokinetics , Rats, Sprague-Dawley , Tandem Mass Spectrometry , Time Factors , Timolol/pharmacokinetics , Treatment Outcome
10.
Open Ophthalmol J ; 10: 146-53, 2016.
Article in English | MEDLINE | ID: mdl-27347250

ABSTRACT

OBJECTIVE: Detrimental effects of the preserved prostaglandin analogs (PGAs) have been thoroughly documented in the published literature. The current work studied two preservative-free (PF) prostaglandin eye drops: PF tafluprost and PF latanoprost. The aim of the study was to compare these two PF formulations in vitro for viability of the human corneal epithelial (HCE-T) cells and in vivo for ocular tolerability of the rabbit eye. METHOD: Viability of the HCE-T cells was measured by the MTS assay. The SV40-immortalized HCE-T cells were exposed to 100 µL of the drug solutions (at their commercial concentrations) or the culture medium. Ocular irritation was evaluated after repeated instillation of the drug solutions in Japanese white rabbits (Kbl:JW). RESULTS: A significant loss of HCE-T cell viability was observed in vitro immediately after the exposure to PF latanoprost formulation but not immediately after the exposure to PF tafluprost formulation. Congruently, PF latanoprost induced in vivo more irritation on the rabbit eye than PF tafluprost. CONCLUSION: Comparing these two PF formulations in vitro and in vivo, it is considered that ocular tolerability of PF tafluprost is better than PF latanoprost. Taking into account the composition of these two PF PGA formulations, the solubilizing agent macrogolglycerol hydroxystearate 40 (MGHS40) contained in PF latanoprost formulation is a plausible cause for the negative effects.

11.
J Ocul Pharmacol Ther ; 31(9): 518-24, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26325164

ABSTRACT

PURPOSE: To assess the usefulness of 0.0015% tafluprost and 0.5% timolol fixed-dose combination (TT-FDC) for glaucoma, the ocular hypotensive effect of TT-FDC and concentration of tafluprost and timolol in the aqueous humor were compared with those of the concomitant administration of 0.0015% tafluprost and 0.5% timolol with or without an appropriate administration interval. METHODS: The ocular hypotensive effect was assessed by intraocular pressure (IOP) measurement in cynomolgus monkeys. Drug penetration into the aqueous humor was estimated by the concentrations of tafluprost acid (active metabolic form of tafluprost) and timolol, which were measured using liquid chromatography-tandem mass spectrometry after administration of tafluprost and timolol to Sprague Dawley rats. RESULTS: The ocular hypotensive effect of TT-FDC was equivalent to that of the concomitant administration of timolol and tafluprost at a more than 5-min interval in monkeys. However, the ocular hypotensive effect of the concomitant administration of timolol and tafluprost without an interval (-2.8 ± 0.2 mmHg at peak IOP reduction) was significantly weaker compared with TT-FDC (-4.3 ± 0.5 mmHg at peak IOP reduction, P = 0.008 vs. concomitant administration of timolol and tafluprost) in monkeys. The aqueous humor concentration of the second administered drug (tafluprost) was not affected by the dosing conditions, whereas the concentration of the first instilled drug (timolol) without the interval was lower than that with a 5-min interval (1,200 ng · h/mL vs. 1,890 ng · h/mL in AUC0-4) in rats. CONCLUSION: TT-FDC demonstrates a clear benefit by preventing efficacy loss without an appropriate interval in experimental animal models.


Subject(s)
Antihypertensive Agents/pharmacology , Glaucoma/drug therapy , Prostaglandins F/pharmacology , Timolol/pharmacology , Administration, Ophthalmic , Animals , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/pharmacokinetics , Aqueous Humor/metabolism , Chromatography, Liquid/methods , Disease Models, Animal , Drug Combinations , Female , Glaucoma/pathology , Intraocular Pressure/drug effects , Macaca fascicularis , Male , Ocular Hypertension/drug therapy , Prostaglandins F/administration & dosage , Prostaglandins F/pharmacokinetics , Rats , Rats, Sprague-Dawley , Tandem Mass Spectrometry/methods , Timolol/administration & dosage , Timolol/pharmacokinetics
12.
Invest Ophthalmol Vis Sci ; 55(2): 1040-7, 2014 Feb 20.
Article in English | MEDLINE | ID: mdl-24458152

ABSTRACT

PURPOSE: To determine whether optical coherence tomography (OCT) is a useful technique to monitor retinal damage and to evaluate the neuroprotective effect of topical tafluprost in a rat model of intravitreal endothelin-1 (ET-1) injection. METHODS: A single intravitreal injection of ET-1 (0.2-200 pmol/eye) was performed in one eye. Optical coherence tomography imaging was performed until 2 weeks after ET-1 injection. Subsequently, an intravitreal injection of ET-1 (20 pmol/eye) was performed in one eye of each rat, which was followed by topical instillation of tafluprost or saline once daily for 4 weeks. Optical coherence tomography imaging was performed until 4 weeks after ET-1 injection. After the last OCT session, retinal ganglion cells (RGCs) were retrogradely labeled with Fluorogold. RESULTS: Endothelin-1 at doses of 20 to 200 pmol/eye caused a significant decrease in inner retinal thickness, whereas ET-1 at doses of 0.2 to 5 pmol/eye did not. The inner retinal thickness at 2 weeks postinjection was strongly correlated with Fluorogold-labeled RGC counts in the central retina (r = 0.92, P < 0.001). The inner retina of eyes treated with tafluprost was significantly thicker than eyes treated with saline at 1 and 2 weeks (P = 0.038 and P = 0.045, respectively). Fluorogold-labeled RGC counts in the central retina of eyes treated with tafluprost were significantly greater than in eyes treated with saline (P = 0.03). CONCLUSIONS: Optical coherence tomography is useful for monitoring inner retinal damage in a rat model of intravitreal ET-1 injection. Daily topical administration of tafluprost may be protective against ET-1-induced retinal injury in the rat.


Subject(s)
Endothelin-1/toxicity , Neuroprotective Agents/therapeutic use , Prostaglandins F/therapeutic use , Retinal Diseases/prevention & control , Retinal Ganglion Cells/drug effects , Tomography, Optical Coherence , Animals , Axons/drug effects , Axons/pathology , Cell Count , Intravitreal Injections , Male , Neuroprotective Agents/administration & dosage , Prostaglandins F/administration & dosage , Rats , Rats, Inbred BN , Retinal Diseases/chemically induced , Retinal Ganglion Cells/pathology
13.
Exp Eye Res ; 119: 97-105, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24321889

ABSTRACT

We investigated the effects of Src-family tyrosine kinase (SFK) inhibitors on intraocular pressure (IOP) and trabecular meshwork (TM) cells. The SFK inhibitors, PP2, PP1, and damnacanthal, significantly lowered IOP from baseline following intracameral injection in ocular normotensive rabbits, and PP2 decreased trans-epithelial electrical resistance (TEER) of TM cell layers in a dose-dependent manner ranging from 0.1 µM to 100 µM. The maximal efficacy of PP2 on TEER was a reduction to 71.7% relative to the vehicle-treated group at 100 µM. PP2 decreased the adhesion of TM cells to culture surfaces either uncoated with specific ECM proteins dose-dependently or coated with extracellular matrix proteins such as laminin I, fibronectin, collagen type I and basement membrane extraction. Tyrosine phosphorylation of focal adhesion kinase and p130(cas) was decreased by PP2. On the other hand, major changes in actin staining of TM cells were not able to be detected after PP2 treatment, although quantitative analysis showed that PP2 induced some morphological changes which were in the different direction to those caused by Y-27632, a Rock inhibitor. Y-27632 at 10 µM increased the permeability of TM cell layers, but did not induce changes in the adhesion of TM cells. These results suggest that SFK inhibitors lower IOP, at least partly, by acting on TM cells in a manner that is distinct from Rock inhibitors.


Subject(s)
Glaucoma/drug therapy , Intraocular Pressure/drug effects , Pyrazoles/pharmacology , Pyrimidines/pharmacology , Trabecular Meshwork/drug effects , rho-Associated Kinases/antagonists & inhibitors , src-Family Kinases/antagonists & inhibitors , Animals , Cell Survival , Cells, Cultured , Disease Models, Animal , Enzyme Inhibitors/pharmacology , Glaucoma/enzymology , Glaucoma/physiopathology , Humans , Microscopy, Confocal , Rabbits , Trabecular Meshwork/enzymology , Trabecular Meshwork/pathology
14.
Hum Mol Genet ; 19(13): 2606-15, 2010 Jul 01.
Article in English | MEDLINE | ID: mdl-20388642

ABSTRACT

Glaucoma is one of the leading causes of bilateral blindness affecting nearly 8 million people worldwide. Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) and is often associated with elevated intraocular pressure (IOP). However, patients with normal tension glaucoma (NTG), a subtype of primary open-angle glaucoma (POAG), develop the disease without IOP elevation. The molecular pathways leading to the pathology of NTG and POAG are still unclear. Here, we describe the phenotypic characteristics of transgenic mice overexpressing wild-type (Wt) or mutated optineurin (Optn). Mutations E50K, H486R and Optn with a deletion of the first (amino acids 153-174) or second (amino acids 426-461) leucine zipper were used for overexpression. After 16 months, histological abnormalities were exclusively observed in the retina of E50K mutant mice with loss of RGCs and connecting synapses in the peripheral retina leading to a thinning of the nerve fiber layer at the optic nerve head at normal IOP. E50K mice also showed massive apoptosis and degeneration of entire retina, leading to approximately a 28% reduction of the retina thickness. At the molecular level, introduction of the E50K mutation disrupts the interaction between Optn and Rab8 GTPase, a protein involved in the regulation of vesicle transport from Golgi to plasma membrane. Wt Optn and an active GTP-bound form of Rab8 complex were localized at the Golgi complex. These data suggest that alternation of the Optn sequence can initiate significant retinal degeneration in mice.


Subject(s)
Eye Proteins/genetics , Eye Proteins/metabolism , Glaucoma/genetics , Retinal Degeneration/genetics , rab GTP-Binding Proteins/metabolism , Amino Acid Substitution , Animals , Apoptosis , Cell Cycle Proteins , Membrane Transport Proteins , Mice , Mice, Inbred Strains , Mice, Transgenic , Mutant Proteins/genetics , Mutant Proteins/metabolism , Optic Nerve/pathology , Protein Binding , Retinal Ganglion Cells/pathology
15.
J Ocul Pharmacol Ther ; 25(3): 179-86, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19456251

ABSTRACT

AIM: Poor topical bioavailability and ocular irritation have impeded the development of the diuretic, ethacrynic acid (ECA) as a clinically useful ocular hypotensive for the treatment of glaucoma. Thus, the development of analogs and prodrugs of analogs with improved ocular penetration, potency, and tolerability is required. The aim of this work is to evaluate the corneal penetration and ocular distribution of SA9000, an ECA analog. Novel SA9000 prodrugs intended to further improve ocular pharmacodynamic effect were also evaluated. RESULTS: SA9000 penetrated porcine corneas more effectively than ECA in corneal diffusion studies. In vivo studies in Dutch-belted (DB) rabbits indicated that topical application of a single dose (0.3%) of SA9000 could significantly reduce intraocular pressure (IOP) (approximately 25% vs. fellow untreated eye) but caused significant conjunctival hyperemia. Since this hyperemia was likely the result of its inherent thiol reactivity, SA9000 was formulated with equimolar cysteine, an exogenous thiol donor. The administration of increasing SA9000-cysteine adduct concentrations (0.3%, 0.6%, 0.9%) demonstrated that they cause less ocular irritation than unadducted SA9000 but could still significantly reduce IOP (0.3%: 8.7 +/- 2%; 0.6%: 14.4 +/- 5%; 0.9%: 23.3 +/- 4.4%) versus untreated contralateral control eyes. CONCLUSIONS: These data suggest that novel thiol donor adduction can improve the ocular bioavailability and tolerability of SA9000. SA9000-cysteine prodrugs may represent a new option for the topical treatment of glaucoma.


Subject(s)
Cinnamates/pharmacology , Ethacrynic Acid/analogs & derivatives , Intraocular Pressure/drug effects , Prodrugs/pharmacology , Administration, Topical , Animals , Biological Availability , Chromatography, High Pressure Liquid , Cinnamates/administration & dosage , Cinnamates/pharmacokinetics , Conjunctiva/blood supply , Conjunctiva/drug effects , Conjunctival Diseases/chemically induced , Cornea/metabolism , Cysteine/administration & dosage , Cysteine/pharmacokinetics , Cysteine/pharmacology , Dose-Response Relationship, Drug , Drug Combinations , Ethacrynic Acid/administration & dosage , Ethacrynic Acid/pharmacokinetics , Ethacrynic Acid/pharmacology , Hyperemia/chemically induced , In Vitro Techniques , Male , Ophthalmic Solutions , Permeability , Prodrugs/administration & dosage , Prodrugs/pharmacokinetics , Rabbits
16.
Biol Pharm Bull ; 30(8): 1445-9, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17666801

ABSTRACT

To evaluate the pharmacological characteristics of SA12590, a new oxime-derivative of the ethacrynic acid (ECA) derivative SA9000, we examined both its ocular hypotensive effects (in ocular normotensive cats and cynomolgus monkeys) and its potential corneal toxicity (in rats). A 50 microl topical administration of 3% SA12590 significantly reduced intraocular pressure (IOP) (by 3.5 mmHg) in anesthetized cats (p<0.05). Twenty-four hours after 3 drops (5-min intervals) of 20 microl 3% SA12590, IOP was reduced by 8 mmHg (p<0.05, n=4) in conscious monkeys without evidence of corneal toxicity. Three days' daily single 20 microl dosing with 3% SA12590 reduced IOP by 4 mmHg (p<0.01, n=3) at 72 h after the first administration in conscious monkeys. The toxicity of topically administered 20 microl 3% SA9000 or SA12590 (3 drops with 5-min intervals) on rat corneal epithelium was assessed using a photo-slit lamp. In this study, 3% SA12590, unlike 3% SA9000, exhibited no corneal toxicity. In a glutathione assay for sulfhydryl (SH) reactivity, SA12590, unlike SA9000, displayed no in vitro SH reactivity. Thus, oxime-modification may both improve efficacy towards IOP upon topical administration and improve the safety profile, probably by enhancing corneal penetration and minimizing SH reactivity-related toxicity. These findings indicate that SA12590 has potential as a new ocular hypotensive drug.


Subject(s)
Diuretics/pharmacology , Ethacrynic Acid/analogs & derivatives , Ethacrynic Acid/pharmacology , Intraocular Pressure/drug effects , Oximes/pharmacology , Administration, Topical , Animals , Cats , Cinnamates/administration & dosage , Cinnamates/pharmacology , Corneal Diseases/chemically induced , Corneal Diseases/pathology , Epithelium, Corneal/drug effects , Epithelium, Corneal/pathology , Ethacrynic Acid/administration & dosage , Macaca fascicularis , Rats , Rats, Sprague-Dawley , Species Specificity
18.
Cardiovasc Drug Rev ; 24(1): 1-10, 2006.
Article in English | MEDLINE | ID: mdl-16939629

ABSTRACT

Elevated intraocular pressure (IOP) is one of the most important risk factors for the development of glaucoma, which is a progressive optic neuropathy. Lowering IOP is currently the only therapeutic approach to the therapy of glaucoma. Since the use of pilocarpine eye drops for glaucoma treatment was reported in the late 1870s, academic researchers and pharmaceutical companies attempted to discover new drugs with more potent, prolonged, and safer IOP-reducing effects. These persistent efforts finally paid off, and prostanoids with FP-receptor agonist activity were found to be very potent IOP-lowering agents. To date, three prostanoids (latanoprost, travoprost and bimatoprost) have been launched in many countries, and now a new FP-receptor agonist, tafluprost, is entering clinical development. All of these prostanoids are superior to the beta-adrenoceptor antagonists in their IOP-lowering efficacy, and no severe side effects have been reported in their long-term clinical use. In addition, tafluprost may be expected to improve ocular blood flow. Hence, prostanoids currently occupy center stage among glaucoma medications. It cannot be denied that in terms of efficacy, safety, patient compliance, and medical economy prostanoids are currently the first-line medicines among ocular antihypertensive drugs.


Subject(s)
Glaucoma/drug therapy , Intraocular Pressure/drug effects , Prostaglandins , Humans , Prostaglandins/pharmacology , Prostaglandins/therapeutic use , Randomized Controlled Trials as Topic , Receptors, Prostaglandin/agonists
19.
Exp Eye Res ; 83(3): 629-37, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16677631

ABSTRACT

The purpose of this study was to investigate the time course of the ocular hypoperfusion, retinal damage, and optic nerve damage induced by intravitreal injection of endothelin-1 (ET-1) in rabbits. ET-1, at 5 pmol (20 microL, twice a week for 2 or 4 weeks), was injected from the pars plana into the posterior vitreous of the right eye. Optic nerve head (ONH) blood flow and retinal artery diameter, together with the neurofilament light chain (NF-L) content, retinal morphology, and axon density of the optic nerve, were evaluated at 2, 4, and 8 weeks after the first injection of ET-1 (n=7 or 8). Tissue blood velocity in ONH was measured using a laser speckle method, and the diameter of major retinal arteries on the rim of the ONH was calculated from fundus photographs by a masked observer. Histological analysis and immunoblot evaluation of NF-L in the optic nerve were performed to evaluate optic nerve damage. At 2 weeks after the first ET-1 injection, tissue blood velocity was decreased by approximately 20% (versus the contralateral eye), and the diameter of retinal arteries had decreased by approximately 40%. These changes were sustained at the same level until 8 weeks after the first ET-1 injection. At 4 and 8 weeks after the first ET-1 injection, the amount of NF-L in the optic nerve was significantly less in the ET-1 treated eyes than in the contralateral eyes. At 8 weeks after the first ET-1 injection, a loss of myelinated axons and increases in gliosis and connective tissue were noted in the optic nerve of the treated eye, and the optic nerve-axon number had decreased significantly (each, versus the untreated eye). Retinal ganglion cells in the retina were not observed any damage at 2, 4, and 8 weeks after ET-1 injection. In conclusion, intravitreal injection of ET-1 induced chronic hypoperfusion in the ONH and retina, which presumably caused decreases in NF-L content and axon number in the optic nerve noted in the later part of the observation period.


Subject(s)
Endothelin-1/pharmacology , Optic Disk/blood supply , Optic Disk/drug effects , Optic Neuropathy, Ischemic/pathology , Animals , Axons/pathology , Blood Flow Velocity/drug effects , Cell Count , Immunoblotting , Injections , Intraocular Pressure , Neurofilament Proteins/analysis , Optic Disk/pathology , Optic Neuropathy, Ischemic/physiopathology , Rabbits , Retina/pathology , Retinal Artery/drug effects , Retinal Artery/pathology , Time Factors , Vitreous Body
20.
Curr Neurovasc Res ; 3(2): 81-8, 2006 May.
Article in English | MEDLINE | ID: mdl-16719791

ABSTRACT

The purpose of this study was to examine the effects of endothelin-1 (ET-1) on retrograde axonal transport in the rat optic nerve. Vehicle or ET-1 (0.2, 1, or 5 pmol/eye) were injected into the vitreous body in Sprague-Dawley rats. Retinal vessels were observed, using a fundus camera, before, and at 10 min, 3 days and 7 days after a single intravitreous injection. Two days after the injection, a neuronal tracer, fluoro gold, was administered via the superior colliculi to retrogradely label active retinal ganglion cells (RGCs). Five days after the tracer administration, retrogradely labeled RGCs were evaluated in the flat-mounted retina, and cross sections from each optic nerve were graded for injury by four independent, masked observers. ET-1 at 5 pmol/eye caused a significant constriction of retinal vessels (versus the vehicle-treated group) at 10 min after the injection. Intravitreous injection of ET-1 caused a dose-related decrease in the number of retrogradely labeled RGCs. Injection of 5 pmol/eye ET-1 led to a statistically significant decrease in the number of retrogradely labeled RGCs (versus the vehicle-treated group). ET-1 at 1 and 5 pmol/eye caused histological optic nerve damage (evaluated using a graded scale). The histological optic nerve damage correlated with the number of retrogradely labeled RGCs. In conclusion, a single intravitreous injection of ET-1 impaired retrograde axonal transport in the rat optic nerve and this impairment correlated with the histological optic nerve damage.


Subject(s)
Axonal Transport/drug effects , Endothelin-1/adverse effects , Glaucoma, Open-Angle/physiopathology , Optic Disk/physiopathology , Optic Neuropathy, Ischemic/physiopathology , Retinal Degeneration/physiopathology , Animals , Axonal Transport/physiology , Axons/drug effects , Axons/pathology , Disease Models, Animal , Dose-Response Relationship, Drug , Endothelin-1/metabolism , Glaucoma, Open-Angle/complications , Male , Optic Disk/blood supply , Optic Disk/drug effects , Optic Neuropathy, Ischemic/chemically induced , Optic Neuropathy, Ischemic/pathology , Rats , Rats, Sprague-Dawley , Retinal Artery/drug effects , Retinal Artery/physiopathology , Retinal Degeneration/chemically induced , Retinal Degeneration/pathology , Retinal Ganglion Cells/drug effects , Retinal Ganglion Cells/pathology , Stilbamidines , Vasoconstriction/drug effects , Vasoconstriction/physiology , Wallerian Degeneration/chemically induced , Wallerian Degeneration/pathology , Wallerian Degeneration/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...